A Phase 3 interventional study of PRC-063 oral capsules and Placebo oral capsules in ADHD, sponsored by Purdue Pharma, Canada. Completed at 6 sites in United States. Open to participants aged 6 Years to 12 Years. Per ClinicalTrials.gov, last updated 2019-11-05.
Sponsored by Purdue Pharma, Canada · Phase 3, Interventional, and Treatment
This is a randomized, double-blind, parallel group, placebo-controlled, dose optimized, phase 3 study to evaluate the safety and efficacy of PRC-063 in the treatment of ADHD in pediatric subjects between 6 to 12 years of age.
Purdue Pharma, Canada is the lead sponsor of 5 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
PRC-063 25, 35, 45, 55, 70 or 85 mg
Drug: PRC-063 oral capsules
Drug: Placebo oral capsules
Daily dose
Daily dose
Swanson, Kotkin, Agler, M-Flynn and Pelham (SKAMP)-Combined Scores During the Full-Day Laboratory Classroom
The SKAMP rating scale is a validated tool that assesses behavioral symptoms of ADHD in a classroom setting. The SKAMP-C comprises 13 items (including subscales: attention with items 1-4, deportment with items 5-8, quality of work with items 9-11 and compliance with items 12-13), and is obtained by summing up each item score where each item is rated on a 7-point impairment scale (0 = none, 6 = maximal impairment), for a total possible combined score of 0 to 78 (lower score indicated fewer ADHD symptoms). During the Full-day Classroom visit, SKAMP-C was assessed at pre-dose and approximately 1, 2, 4, 6, 8, 10, 12, and 13 hours post-dose. Average post-dose score and change from pre-dose score were analyzed on the individual SKAMP-C scores.
Time frame: Full-day Classroom - 13 hrs
| Milestone | PRC-063 | Placebo |
|---|---|---|
| Started | 156 | 0 |
| Completed | 148 | 0 |
| Not completed | 8 | 0 |
| Milestone | PRC-063 | Placebo |
|---|---|---|
| Started | 75 | 73 |
| Completed | 74 | 73 |
| Not completed | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 |
The SKAMP rating scale is a validated tool that assesses behavioral symptoms of ADHD in a classroom setting. The SKAMP-C comprises 13 items (including subscales: attention with items 1-4, deportment with items 5-8, quality of work with items 9-11 and compliance with items 12-13), and is obtained by summing up each item score where each item is rated on a 7-point impairment scale (0 = none, 6 = maximal impairment), for a total possible combined score of 0 to 78 (lower score indicated fewer ADHD symptoms). During the Full-day Classroom visit, SKAMP-C was assessed at pre-dose and approximately 1, 2, 4, 6, 8, 10, 12, and 13 hours post-dose. Average post-dose score and change from pre-dose score were analyzed on the individual SKAMP-C scores.
| score on SKAMP-C | PRC-063 | Placebo |
|---|---|---|
| Swanson, Kotkin, Agler, M-Flynn and Pelham (SKAMP)-Combined Scores During the Full-Day Laboratory Classroom | 11.4 ± 6.9 | 18.2 ± 9.0 |
Collected over 12 weeks. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| PRC-063 | 0/74 (0%) | 0/74 (0%) | 10/74 (13.5%) |
| Placebo | 0/73 (0%) | 0/73 (0%) | 3/73 (4.1%) |
| Event | PRC-063 | Placebo |
|---|---|---|
| Heart Rate IncreasedInvestigations | 3/74 | 1/73 |
| Sinus TachycardiaCardiac disorders | 1/74 | 2/73 |
| VomitingGastrointestinal disorders | 2/74 | 0/73 |
| HeadacheNervous system disorders | 2/74 | 0/73 |
| Upper Respiratory Tract InfectionInfections and infestations | 2/74 | 0/73 |
| Age, Customized(years) | PRC-063 | Placebo | Total |
|---|---|---|---|
| Age | 9.4 ± 1.89 | 9.4 ± 1.83 | 9.4 ± 1.85 |
| Sex: Female, Male(Participants) | PRC-063 | Placebo | Total |
|---|---|---|---|
| Female | 27 | 24 | 51 |
| Male | 47 | 49 | 96 |
| Ethnicity (NIH/OMB)(Participants) | PRC-063 | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 21 | 21 | 42 |
| Not Hispanic or Latino | 53 | 52 | 105 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | PRC-063 | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 1 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 25 | 33 | 58 |
| White | 47 | 34 | 81 |
| More than one race | 2 | 5 | 7 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | PRC-063 | Placebo | Total |
|---|---|---|---|
| United States | 74 | 73 | 156 |
Documents are hosted by the registry — open the source record to download them.
This study is completed, as verified in May 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Purdue Pharma, Canada